Affimed hangs onto Genentech alliance after dropping stranded PhI program as CSO exits
Seven months into the full clinical hold the FDA slapped on its Phase I AFM11 program following a patient death, Affimed is scrapping the drug altogether to focus on two other early-stage innate cell engagers — and it will be doing so, for now, without a CSO.
The German biotech made the decision after hearing from regulators earlier this month that additional data would be required before they might resume work on the CD19/CD3-targeting T cell engager said CEO Adi Hoess on a conference call. Running a nimble small biotech operation, he explains, requires a commitment to the efficient allocation of time and resources.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
